

## **Ipilimumab zur Behandlung des fortgeschrittenen Melanoms**

### **L'ipilimumab pour le traitement du mélanome à un stade avancé**

#### **Literatur / Références**

1. Buillard JL, Panizzon RG, Levi F. Epidemiologie und Prävention des Hautmelanoms in der Schweiz: Update 2010. *Akt Dermatol.* 2010;36:408–13.
2. Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, et al. New challenges in endpoints for drug development in advanced melanoma. *Clin Cancer Res.* 2012;18(2):336–41.
3. Lens M, Testori A, Ferucci PF. Ipilimumab Targeting CD28-Ctla-4 Axis: New Hope in the Treatment of Melanoma. *Curr Top Med Chem.* 2012;12(1):61–6.
4. Dummer R, Guggenheim M, Arnold AW, Brauna R, von Moos R. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. *Swiss Med Wkly.* 2011;141:w13320.
5. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. *Cancer Biother Radiopharm.* 2010;25(6):601–13.
6. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer. *Curr Opin Immunol.* 2006;16:206.
7. Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? *Oncologist.* 2009;14(8):848–61.
8. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: A review. *Crit Rev Immunol.* 1998;18(5):389–418.
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med.* 2010;363(8):711–23. Erratum in: *N Engl J Med.* 2010;363(13):1290.
10. Robert C, Thomas L, Bondarenko I, O'Day S, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med.* 2011;364(26):2517–26.
11. Yervoy® (Ipilimumab): Fachinformation im Arzneimittelkompendium der Schweiz, [www.documed.ch](http://www.documed.ch).
12. Zelboraf® (Vemurafenib): Fachinformation im Arzneimittelkompendium der Schweiz, [www.documed.ch](http://www.documed.ch).